Nippon Shinyaku Co., Ltd. (日本新薬株式会社, Nihon Shinyaku Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Kyoto, Japan. Founded in 1919, Nippon Shinyaku has evolved from a traditional Japanese medicine (Kampo) manufacturer into a modern innovative pharmaceutical company with strong capabilities in oncology, hematology, urology, and rare diseases. The company has recently expanded into neuroscience, with a focus on neurodegenerative diseases.
| Attribute | Details |
|---|---|
| Headquarters | Kyoto, Japan |
| Founded | 1919 |
| Stock Ticker | TSE: 4516 |
| Revenue | ¥102.3 billion (FY2023) |
| Employees | ~4,200 |
| President & CEO | Masaki Togawa |
| Website | www.nippon-shinyaku.co.jp |
Nippon Shinyaku was founded in 1919 as a manufacturer of traditional Japanese medicines and pharmaceutical ingredients. The company was established in Kyoto, maintaining its headquarters in this historic city to this day.
During the 1960s and 1970s, Nippon Shinyaku transitioned from traditional medicines to modern pharmaceutical development. The company established research facilities and began developing innovative drugs.
Nippon Shinyaku has become known for specialty pharmaceuticals, particularly in oncology and hematology. The company has more recently entered the neuroscience field through strategic partnerships and internal research.
Nippon Shinyaku has developed several important anticancer agents, including:
The company has a strong presence in hematology with products for:
Nippon Shinyaku has developed treatments for rare conditions:
Recent expansion into neurodegenerative diseases includes:
| Compound | Indication | Stage | Mechanism |
|---|---|---|---|
| NS-101 | Alzheimer's Disease | Preclinical | BACE1 inhibitor |
| NS-205 | Parkinson's Disease | Discovery | Alpha-synuclein aggregation inhibitor |
| NS-300 | ALS | Preclinical | SOD1 targeting |
| NS-400 | Huntington's Disease | Discovery | Huntingtin protein modulation |
Nippon Shinyaku's neuroscience strategy focuses on:
While not yet marketed, Nippon Shinyaku has expressed interest in:
Nippon Shinyaku maintains collaborations with:
Nippon Shinyaku demonstrates strong financial performance:
| Metric | FY2023 |
|---|---|
| Revenue | ¥102.3 billion |
| R&D Expenditure | ¥18.5 billion (18.1%) |
| Operating Income | ¥26.8 billion |
| Net Income | ¥19.2 billion |
| Market Cap | ~¥280 billion |
The company has increased R&D investment in neuroscience as a strategic priority.
Nippon Shinyaku's corporate mission emphasizes:
Nippon Shinyaku engages in various CSR activities:
Nippon Shinyaku's future strategy includes: